Group items matching

in title, tags, annotations or url

The National Health Service will begin its autumn Covid vaccine program next week, a month earlier than planned in response to the spread of a new variant dubbed Pirola. Covid vaccines will be administered to care home residents and housebound individuals from Monday onwards, while over-65s and other vulnerable groups will receive their appointments the week after. On Aug. 30, NHS England shifted the autumn vaccination drive to start on September 11 in response to the new Covid-19 variant, BA.2.86, detected on August 18. The primary groups can book through a national system upon receiving an invitation from the NHS. Some people may get an earlier call from their GP, and a few have already scheduled Covid vaccinations alongside their flu jabs. The NHS will begin inviting other eligible groups from Sept. 18. However, it is important to note that not everyone will receive a call at the same time. These groups will include individuals aged 65 and over, those aged six months to 64 years in a clinical risk category, frontline health and social care workers, and individuals aged 12 to 64 who are carers or household contacts of those with immunosuppression.

The Medicines & Healthcare products Regulatory Agency has initiated a recall of three batches of Quantum Pharmaceutical's Diltiazem HCl 2% Cream, which is an unlicensed medicine. MHRA issued a precautionary recall of the cream due to a change in the product's appearance that affected its thickness. Pharmacists are instructed to halt supply, quarantine remaining stock, and contact Quantum Pharmaceutical to return affected batches M1402497, M1402574, and M1402680. Patients using this product may encounter application issues with the cream due to its consistency. However, MHRA said that this has not impacted the product's effectiveness or posed any risk to patient safety. The MHRA also reported that medac GmbH (t/a medac Pharma LLP) is conducting a recall of two batches of Sodiofolin 50 mg/ml solution for injection/infusion (400mg/8ml vial) with batch numbers G220393B and G220393C. This class 2 medicines recall is a result of particles detected during long-term stability tests.

Drugmakers GSK, Pfizer, Sanofi and Boehringer Ingelheim on Tuesday were spared thousands of US lawsuits claiming that the heartburn drug Zantac caused cancer, as a judge found the claims were not backed by sound science. The ruling by US District Judge Robin Rosenberg in West Palm Beach, Florida, knocks out about 50,000 claims in federal court, though it does not directly affect tens of thousands of similar cases pending in state courts around the country. "We are extremely surprised by this miscarriage of justice," and "fully expect" the ruling will be reversed on appeal, lawyers for the plaintiffs said in a joint statement. A Sanofi spokesperson said the decision "significantly decreases the scope of the litigation potentially by over 50 per cent," with the remaining litigation being only in state court. A spokesperson for GSK said the company welcomed the decision and Pfizer said it was pleased by the outcome. Privately-held German drugmaker Boehringer said in a statement that it looked forward to "continuing our vigorous defense of the remaining cases in state courts."

The Pharmacists' Defence Association (PDA) has made the its 'Education revision programme' accessible for new registrations who are preparing for the GPhC/PSNI November 2022 assessment. The programme offers a wide range of practice calculations questions, some mock exams, practical tips on revision, and an opportunity to chat to other PDA members who are preparing to sit the assessment. PDA's charity partners, Pharmacist Support also offer a range of options including- Counselling and peer support; Financial support; A listening friend service and Addiction support. Candidates can also access the Wardley Wellbeing Service here. This is a resource to help candidates to prioritise their mental, physical and emotional health through individual and group training. The PDA has also reminded all candidates that there have been some changes made by the GPhC to address problems that occurred in the June 2022 sitting.

Britain has approved Novavax's Covid-19 vaccine for use in those 18 years of age and older, the country's medicines regulator said on Thursday (February 3), bringing a fifth coronavirus shot to its roster amidst the rapid spread of the Omicron variant. The vaccine, Nuvaxovid, was approved as a first and second dose as it met the required safety, quality and effectiveness standards, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) said in a statement. The British approval for Nuvaxovid comes days after the drugmaker filed for US authorisation of the vaccine following months of struggles with development and manufacturing problems, and follows a German backing earlier in the day. "We are continuing our vital safety work in monitoring the use of all Covid-19 vaccines, to ensure that their benefits in protecting people against Covid-19 disease continue to outweigh any risks," MHRA chief executive June Raine said.

The drop in vaccination rates is believed to be driving a surge in measles cases in England, mainly in the West Midlands. As of 18 January, 216 confirmed cases and 103 probable cases have been reported in the region since 1 October 2023, the UK Health Security Agency (UKHSA) revealed. The majority of cases (around 80 per cent) were from Birmingham, with children aged under 10 years being infected the most. UKHSA Chief Executive, Professor Dame Jenny Harries has warned that the outbreak could spread further to other towns and cities if urgent action is not taken to increase Measles, Mumps and Rubella (MMR) vaccination uptake in areas at greatest risk.

The Department of Health and Social Care (DHSC) has published the full text of the 2024 voluntary scheme for branded medicines pricing, access and growth (VPAG). The 2024 VPAG agreement text sets out the detailed terms of the agreement reached between DHSC, NHS England and the Association of the British Pharmaceutical Industry (ABPI) to support patient access to medicines, the financial sustainability of the NHS and the UK life sciences sector. The new voluntary scheme will come into force on 1 January 2024, following expiry of the 2019 Voluntary Scheme and shall remain in force for a period of five years, until 31 December 2028. Manufacturers or suppliers of branded medicines to the NHS have been given time till 15 January 2024 to decide whether to join the new 2024 Voluntary Scheme, or default to the updated Statutory Scheme.

Healthcare staff across England are facing increasing winter pressures amid junior doctor's strikes, as thousands of hospital beds are being occupied by patients with flu, norovirus and Covid-19. The number of flu patients in hospital has increased by almost two thirds in a week, according to the latest weekly update from the National health Service (NHS). New NHS figures published on Thursday showed an average of 648 patients were hospitalised with flu per day this week before the industrial action, up from 402 last week. This lasts number is four times the figure reported at the end of last month (160 per in the week ending 26 November).

Period problems, women's health research and support for domestic and sexual abuse victims are among the government's priorities for women's health in 2024, which Health Secretary Victoria Atkins announced at the Women's Health Summit on Wednesday. Organised in central London, the event marked the second year of the landmark Women's Health Strategy for England. Victoria joined women's health champions to celebrate successes of strategy's first year and outlined plans for coming year, which also include improving maternity care and support for mothers who suffer birth trauma. Successes achieved over the strategy's first 12 months include reducing the cost of hormone replacement therapy (HRT) for nearly half a million women and the rollout of specialist women's health hubs in every local health area. A new dedicated women's health section of the NHS website was also created, providing updated information, advice and practical resources for women's health across the life course.

With 118 new cases confirmed by the UK Health Security Agency (UKHSA), the total number of measles cases reported in England since 1 October 2023 has gone up to 465. According to the latest data published by the agency, West Midlands continues to see a disproportionately high rate of infections, with a sharp rise in case numbers over the last six weeks, mainly driven by cases in Birmingham. In England, there were 17 laboratory-confirmed measles cases in October, 42 in November, 161 in December, 240 in January 2024. Five more cases were confirmed last week, according to the measles statistics updated by UKHSA on 8 February. More than 70 per cent (329 of 465) of total confirmed cases were reported from the West Midlands, 13 per cent (62 of 465) from London, seven per cent (32 of 465) in Yorkshire and The Humber, and the remaining cases from other regions of England.

AstraZeneca UK has revised the expiry dates for certain batches of Fluenz Tetra nasal spray vaccines as a precautionary measure, after finding that their potency (strength) dropped faster than predicted once thawed, during routine testing. The Medicines and Healthcare products Regulatory Agency (MHRA) has been informed by the manufacturer that the printed expiry date for a limited number of batches is "incorrect." However, the MHRA has assured patients that the affected batches are safe to use and fully effective within the amended expiry date. If the vaccine is administered after the amended expiry date, it may be less effective in protecting against flu, it said. The UK regulatory authority also reiterated that it "keeps the safety of medicines, including vaccines, under review, and acts where necessary to protect patients and the public."

The Medicines and Health products Regulatory Agency (MHRA) on Thursday issued a class 4 medicines defect information notice for Cozaar 100mg film-coated tablets due to an error in the Patient Information Leaflets (PILs) reported by the company. Cozaar is used to treat high blood pressure (hypertension) as well as to slow the progression of kidney disease in people who have type 2 diabetes mellitus. Quadrant Pharmaceuticals Ltd has informed the UK regulatory authority that the PILs that have been packed in certain batches of the products do not have the most up to date safety information. 'Grapefruit juice should be avoided while taking Cozaar'- This information is missing in Section 2 'What you need to know before you take Cozaar', sub section 'Cozaar with food and drink', the company clarified.

London's Great Ormond Street Hospital and Alder Hey Children's Hospital in Liverpool are poised to introduce groundbreaking gender-related services in England, following the closure of the Gender Identity Development Service (Gids) operated by the Tavistock and Portman NHS Foundation Trust. Amid concerns expressed by hospital executives regarding the closure of Gids, with leaked emails revealing apprehensions about appointment cancellations and inadequate communication with the new services, the National Health Services England (NHSE) has confirmed "its commitment to ensuring continuity of care for patients already accessing endocrine care in GIDS." NHSE's decision to transition to regional services stems from a 2022 interim review, led by Dr. Hilary Cass, which highlighted the need for improved support structures for gender-distressed youth. It emphasized a significant increase in referrals to Gids, surpassing 5,000 in 2021/22, compared to less than 250 a decade ago.

The King's condition is "benign" and he will be treated in the hospital next week for a "corrective procedure", Buckingham Palace said a statement released on Wednesday. "In common with thousands of men each year, the King has sought treatment for an enlarged prostate," the Palace said. Because of the upcoming surgery, Charles had to postpone all meetings and events planned for this week. The Palace informed that the King's public engagements will be "postponed for a short period of recuperation." Charles, 75, wanted to share the details of his diagnosis to encourage more men who may be experiencing symptoms to get their conditions checked.

With scarlet fever currently circulating in England, the UK Health Security Agency (UKSHA) has urged parents to remain vigilant for potential symptoms in children. Also known as scarlatina, it is an infectious disease triggered by group A strep bacteria that can lead to symptoms such as fever, a sandpapery rash, sore throat and swollen tonsils. The latest data published by the UKHSA showed that a total of 19,528 cases of scarlet fever were reported in the 2023/24 season, of which 12,176 cases occurring between 1 January and 24 March 2024. While the number of cases recorded this year is lower than those recorded during the same period in 2023, which totaled 15,933 cases, it exceeds the average for the previous five years. "Scarlet fever is a common childhood illness, although it can affect anyone of any age," said Dr Theresa Lamagni at UKHSA. Parents are advised to contact their GP practice or NHS111 when their GP is unavailable, if they suspect they or their child are experiencing symptoms of scarlet fever.

Pfizer on Thursday said a single dose of its new respiratory syncytial virus (RSV) vaccine Abrysvo maintained its ability to protect against the illness through a second year of respiratory disease season. The company said in a press release that the vaccine's efficacy against RSV-associated lower respiratory tract disease with three or more symptoms was 77.8 per cent through season two, compared with efficacy of 88.9 per cent after the first RSV season, which led to the shot's US approval. The data is from a late-stage trial of more than 37,000 participants being conducted in both the Northern and Southern hemispheres. Cumulative efficacy over both seasons after around 16.4 months of disease surveillance was 81.5 per cent, Pfizer said. The data is similar to the efficacy of GSK's rival RSV shot Arexvy over two seasons, which was released in June.

Amid the rapid rise in semaglutide usage, a study has suggested a potential risk of a rare eye condition associated with the weight loss drug. Semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1 RA), is available under the brand name Ozempic (by Novo Nordisk) in a lower-dose form for managing type 2 diabetes mellitus (T2DM), and as Wegovy (also by Novo Nordisk) in a higher-dose form for weight management in patients with high body mass indexes. Anecdotal evidence has indicated that semaglutide might be linked to nonarteritic anterior ischemic optic neuropathy (NAION). To investigate this potential connection, researchers in the United States analysed data over a six-year period from nearly 17,000 neuro-ophthalmology patients at Massachusetts Eye and Ear Hospital in Boston, Massachusetts, all of whom had no prior history of NAION.

In his first speech as Secretary of State for Health and Social Care, Wes Streeting MP acknowledged that the NHS is in crisis while outlining his mission to save the health service. Streeting described the current state of the NHS as "broken," noting its failure to meet the needs of both patients and dedicated healthcare professionals. "When we said during the election campaign, that the NHS was going through the biggest crisis in its history, we meant it. "When we said that patients are being failed on a daily basis, it wasn't political rhetoric, but the daily reality faced by millions," he said on Friday (5 July). The new health secretary remarked that previous governments had been unwilling to admit these simple facts.